ArticleJournal of controlled release : official journal of the Controlled Release Society2013
Polysaccharide-modified scaffolds for controlled lentivirus delivery in vitro and after spinal cord injury.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Development of a gene-activated matrix for enhanced AAV gene deliveryFrontiers in bioengineering and biotechnology · 2026Article
- Lymph-Node Inspired Hydrogels Enhance CAR Expression and Proliferation of CAR T Cells.ACS applied materials & interfaces · 2025Article
- Review
- IL-10 lentivirus-laden hydrogel tubes increase spinal progenitor survival and neuronal differentiation after spinal cord injury.Biotechnology and bioengineering · 2021Article
- Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord.APL bioengineering · 2021Article
- Lentiviral Interleukin-10 Gene Therapy Preserves Fine Motor Circuitry and Function After a Cervical Spinal Cord Injury in Male and Female Mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Molecular and histologic outcomes following spinal cord injury in spiny mice, Acomys cahirinus.The Journal of comparative neurology · 2020Article
- Injectable, Hyaluronic Acid-Based Scaffolds with Macroporous Architecture for Gene Delivery.Cellular and molecular bioengineering · 2019Article
- Recent advances in nanotherapeutic strategies for spinal cord injury repair.Advanced drug delivery reviews · 2019Review
- Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair.Nature reviews. Rheumatology · 2019Review
- Combinatorial lentiviral gene delivery of pro-oligodendrogenic factors for improving myelination of regenerating axons after spinal cord injury.Biotechnology and bioengineering · 2019Article
- Spinal Progenitor-Laden Bridges Support Earlier Axon Regeneration Following Spinal Cord Injury.Tissue engineering. Part A · 2018Article
- Microgels produced using microfluidic on-chip polymer blending for controlled released of VEGF encoding lentivectors.Acta biomaterialia · 2018Article
- Biomaterial Scaffolds in Regenerative Therapy of the Central Nervous System.BioMed research international · 2018Review
- Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.Tissue engineering. Part B, Reviews · 2017Review
- Alginate-Chitosan Hydrogels Provide a Sustained Gradient of Sphingosine-1-Phosphate for Therapeutic Angiogenesis.Annals of biomedical engineering · 2017Article
- Reducing neuroinflammation by delivery of IL-10 encoding lentivirus from multiple-channel bridges.Bioengineering & translational medicine · 2016Article
- Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury.Cells, tissues, organs · 2016Review
- Bridging the lesion-engineering a permissive substrate for nerve regeneration.Regenerative biomaterials · 2015Article
- Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gene delivering biomaterials have increasingly been employed to modulate the cellular microenvironment to promote tissue regeneration, yet low transduction efficiency has been a persistent challenge for in vivo applications. In this report, we investigated the surface modification of poly(lactide-co-glycolide) (PLG) scaffolds with polysaccharides, which have been implicated in binding lentivirus but have not been used for delivery. Chitosan was directly conjugated onto PLG scaffolds, whereas heparin and hyaluronan were indirectly conjugated onto PLG scaffolds with multi-amine crosslinkers. The addition of chitosan and heparin onto PLG promoted the association of lentivirus to these scaffolds and enhanced their transduction efficiency in vitro relative to hyaluronan-conjugated and control scaffolds that had limited lentivirus association and transduction. Transduction efficiency in vitro was increased partly due to an enhanced retention of virus on the scaffold as well as an extended half-life of viral activity. Transduction efficiency was also evaluated in vivo using porous, multiple channel PLG bridges that delivered lentivirus to the injured mouse spinal cord. Transgene expression persisted for weeks after implantation, and was able to enhance axon growth and myelination. These studies support gene-delivering PLG scaffolds for in vivo regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.